AbbVie Inc. — Director's Dealing 2023

Mar 15, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AbbVie Inc. (ABBV)
CIK: 0001551152
Period of Report: 2023-03-13

Reporting Person: Stewart Jeffrey Ryan (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-13	Common Stock, $0.01 par value	M	21810	$54.86	Acquired	114066	Direct
2023-03-13	Common Stock, $0.01 par value	S	21810	$152.30	Disposed	92256	Direct
2023-03-13	Common Stock, $0.01 par value	S	31315	$152.27	Disposed	60941	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-03-13	Option (Right to Buy)	$54.86	M	21810	Disposed	2026-02-17	Common Stock (21810)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, $0.01 par value	1338	Indirect

Footnotes

F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.79 to $152.73 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.79 to $152.73 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The reporting person disclaims beneficial ownership of all securities held by his spouse.

F4: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section16 under Rule 16b-3.